Moreover, mechanism-based therapies are being introduced in genetically defined subgroups, as illustrated by the activity of the HIF-2α inhibitor belzutifan in VHL-associated neoplasms, including non-metastatic pNENs [81,82]. This evidence concerns the gene VHL and neoplasm.